Figure 2
From: Clinical and molecular characterization of HER2amplified-pancreatic cancer
Clinicopathological features of HER2 -amplified pancreatic ductal adenocarcinoma (PDAC). (A) Her2 immunohistochemistry showing 3+ staining, and corresponding HER2 amplification on (B) silver and (C) fluorescence in situ hybridization. Imaging results of patient 9 (Table 2) showing (D) cerebral and (E) lung metastases, and (F) absence of liver metastases.